Last updated: April 25, 2026
Thalomid is the brand name for thalidomide. In practice, “suppliers” split into two layers: (1) brand/marketing authorization and distribution (who can sell the branded product in a given market) and (2) active pharmaceutical ingredient (API) and manufacturing (who produces or supplies the drug substance and finished product).
Because “Thalomid suppliers” depends on country, dosage form (capsules), and package strength, the most defensible supply map is the one tied to product authorization holders and commercial distributors by jurisdiction, plus the known manufacturing chain names that repeatedly appear on regulatory and product documentation.
Who is the brand owner and product supplier for Thalomid?
Pomalyst and Thalomid are marketed by Celgene (Bristol Myers Squibb) in multiple jurisdictions after Celgene’s acquisition history and product portfolio consolidation.
Practical implication for sourcing: for regulated distribution, the “supplier” most relevant to procurement decisions is the authorized marketing entity in the destination market (often BMS/Celgene entities and their local distribution partners), not ad hoc brokers.
Which companies commonly appear in the thalidomide supply chain?
Across filings and commercial packaging documentation for thalidomide products globally, sourcing typically includes:
- API and finished-dose manufacturing contractors in regulated plants (often outside the US/EU footprint)
- packaging and labeling partners in-country or regionally for each market
- brand distributors appointed by the marketing authorization holder
The thalidomide molecule is tightly controlled due to the drug’s safety program history, so procurement typically routes through authorized commercial channels rather than open-market raw material supply.
What does a procurement-ready supplier map look like by supplier type?
1) Brand marketing authorization and distribution
In most markets where Thalomid is available as the commercial brand, the supply counterpart is the Bristol Myers Squibb/Celgene commercial organization, with local distributors depending on country rules (wholesale licensing, tender framework, and REMS-like handling controls).
Supplier entry point for business users: local authorized wholesaler listed on the country’s drug directory for Thalomid (thalidomide) with the marketing authorization holder.
2) Finished-dose manufacturer (capsules)
Finished-dose supply is handled by contract manufacturers under the brand holder’s label and quality system. The drug is typically produced as oral capsule presentations, with market-specific strength variants.
3) API supply (thalidomide drug substance)
API sourcing is from regulated chemical manufacturing sites with validated controls for impurity profile and physical quality. Thalidomide is low-molecular-weight but highly scrutinized for impurity control and handling.
4) Packaging and labeling
Because packaging and labeling are jurisdiction-specific (language, lot coding, and safety communication), the final “supplier you can order from” in a market often reflects the packaging-and-release chain tied to that market’s marketing authorization.
Supplier landscape (actionable view): how companies map to procurement decisions
A. Market access supplier
Procurement teams should map:
- Destination country
- Strength and pack size
- Authorized marketing authorization holder for Thalomid
- Local wholesale channel and release site listed on product documentation
This is the supplier that controls the legal ability to sell the branded product in that market.
B. Manufacturing supplier (operational, not necessarily ordering)
Operational procurement and tech-transfer work should map:
- API manufacturing site(s)
- Finished-dose manufacturer
- Packaging site(s)
- Quality agreement holders and batch release responsibility
This is the supplier chain behind consistent supply, lead time, and discontinuation risk.
Key constraints that shape “who supplies Thalomid”
Thalidomide distribution is shaped by:
- High regulatory scrutiny (risk minimization program mechanics)
- Traceability and lot-level quality requirements
- Authorized channel restrictions that limit informal supply routes
As a result, the “suppliers” that matter for continuity are:
1) the authorized marketing entity in the market, and
2) the contract manufacturers named in regulatory product documentation for that market’s presentations.
What you should expect in supplier documentation for Thalomid
For a procurement or diligence pack, suppliers are usually evidenced through:
- Product label imprinting (manufacturer and packaging lot identifiers)
- Regulatory product monographs in the relevant jurisdiction
- Marketing authorization details (holder and manufacturing sites)
- Wholesale distributor listings in drug directories
- Drug master file references in regulator-facing documentation (where accessible)
Key Takeaways
- “Suppliers for Thalomid” resolves into two layers: authorized brand distribution (by country) and drug substance/finished-dose manufacturing chain (by regulated sites).
- For most jurisdictions, the commercial brand ecosystem is tied to Bristol Myers Squibb/Celgene as the marketing and distribution backbone for Thalomid.
- Procurement-quality sourcing requires mapping the destination country’s authorized wholesaler and release chain for the specific Thalomid strength and pack format, then linking that to the named manufacturing and packaging sites in regulatory product documentation.
FAQs
1) Who supplies Thalomid in most countries?
The branded commercial supply is tied to the Thalomid marketing organization connected to Celgene and Bristol Myers Squibb, with country-specific authorized wholesalers/distributors.
2) Can I source Thalomid API from the open market?
Typically no through compliant channels; thalidomide is controlled through authorized manufacturing and distribution with strict traceability and quality systems.
3) Who manufactures Thalomid capsules?
The capsules are produced by regulated finished-dose contract manufacturers under the brand holder’s quality system; exact sites vary by country and strength.
4) Do packaging sites differ by jurisdiction?
Yes. Packaging and labeling are typically jurisdiction-specific, so packaging and lot-release steps vary by country.
5) What is the most reliable way to identify the correct supplier?
Use the country-specific drug listing for Thalomid to identify the marketing authorization holder and authorized distributor, then cross-reference the label and regulatory monographs for named manufacturing and packaging sites.
References
[1] Bristol Myers Squibb. Product information pages for Thalomid (thalidomide) and brand portfolio context.
[2] FDA. Thalomid (thalidomide) product information and distribution/risk program framework references.
[3] European Medicines Agency (EMA). Thalomid product documentation and assessment materials where available.
